Vitamin D and Calcium Supplement Attenuate Bone Loss among HIVInfected Patients Receiving Tenofovir Disoproxil Fumarate/Emtricitabine/ Efavirenz: An Open-Label, Randomized Controlled Trial.

Plain-language guide to PMID 31906840 (2020): open-label randomized controlled trial of Vitamin D, K2, Magnesium and Zinc and Copper (Supplement).

Key Facts

PMID: 31906840
Journal: Current HIV research
Year: 2020
Study type: Randomized Controlled Trial
Authors: Boontanondha P et al. (5 authors)
DOI: 10.2174/1570162X18666200106150806

What This Study Did, in Plain Language

What Was Tested

The paper reports a study of Vitamin D, K2, Magnesium and Zinc and Copper (Supplement), published as a randomized controlled trial.

The researchers aimed to determine the effect of vitamin D2 and calcium on bone mineral density (BMD) in HIV-infected patients receiving TDF/emtricitabine (FTC)/efavirenz (EFV).

Who Took Part

By PubMed's age tags, the people studied were teenagers, young adults, adults and middle-aged adults, both men and women.

Eligible patients were ART naïve HIV individuals who initiated TDF/FTC/EFV.

The study group received supplementation with vitamin D2 and calcium carbonate, whereas the control group was administered only ART.

How the Study Was Run

The researchers set it up as a randomized and open-label study.

Because people in this Vitamin D, K2, Magnesium and Zinc study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Being open-label, the Vitamin D, K2, Magnesium and Zinc study did not mask who received what.

A prospective, open-label, randomized controlled study was conducted.

The primary outcome was the percentage change in total hip BMD at week 24 compared with baseline.

What Was Measured

PubMed files the paper under topics including Anti-HIV Agents, Antiretroviral Therapy, Highly Active, Bone Density Conservation Agents, Bone Resorption, Calcium Carbonate, Efavirenz, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination and Femur Neck.

The authors tagged it with the keywords Bone loss, bone mineral density and vitamin D.

What This Means in Plain Language

The paper is a randomized and open-label study of Vitamin D, K2, Magnesium and Zinc and Copper (Supplement).

Its findings take up roughly 8 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2020 (Current HIV research), a journal based in Netherlands.

More context: the Vitamin D, K2, Magnesium and Zinc compound page and the Copper (Supplement) compound page, all human trials.

Our Notes on the Compounds

Vitamin D, K2, Magnesium and Zinc: Magnesium is described as required for AMPK to function.

Copper (Supplement): The active site of cytochrome c oxidase is described as containing copper ions that are essential for electron transfer.

Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.